Search
Now showing items 11-20 of 35
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
(Oxford University Press, 2015-12-24)
[Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ...
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
(Wiley, 2016-06-06)
[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ...
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin
(Springer, 2015-07-09)
[Abstract] It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, ...
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
(Taylor & Francis, 2019-01-03)
[Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in ...
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
(Elsevier, 2017-01-18)
[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated.
Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ...
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
(Plos ONE, 2019-06-03)
[Abstract] BACKGROUND:
Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ...
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
(Frontiers, 2019-08-03)
[Abstract] In Western Europe, the HIV-1 epidemic among men who have sex with men (MSM) is
dominated by subtype B. However, recently, other genetic forms have been reported to
circulate in this population, as evidenced ...
Effectiveness and Safety of Sofosbuvir/Velpatasvir ± Ribavirin vs Glecaprevir/Pibrentasvir in Genotype 3 Hepatitis C Virus Infected Patients
(BMJ Publishing Group, 2020-02-07)
[Abstract]
Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ...
Deep-Sequencing Reveals Broad Subtype-Specific HCV Resistance Mutations Associated with Treatment Failure
(Elsevier, 2019-12-16)
[Abstract]
A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was ...
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
(Sociedad Española de Quimioterapia, 2019)
[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ...